Archive for the ‘Blood / Hematology’ Category

PATHFAST(R): Rapid Whole Blood Immunoassay Analyzer From Polymedco

Saturday, April 12th, 2008

Polymedco, Inc. is pleased to announce the introduction of the PATHFAST immunoassay analyzer. The PATHFAST rapid point of care system utilizes a chemiluminescent technology combined with a unique magtration separation method that allows this system to report highly accurate results that compare to large platform instruments. The PATHFAST system ...

EBMT Has Successful Finish To 34th EBMT Annual Congress, Plans For The Coming Year

Thursday, April 10th, 2008

The 34th Annual Congress of the European Group for Blood and Marrow Transplantation (EBMT) closed its session on the afternoon of 2 April 2008, wrapping up a successful five day Congress with a range of activities, informational sessions, and workshops. This years Congress had a record number of 4,713 ...

Too Much Of A Good Thing: High Levels Of Factor VIIa Cause Problems In Mice

Thursday, April 10th, 2008

Individuals with hemophilia lack either factor VIII or factor IX, proteins crucial for the cascade of events that leads to blood clotting. Although individuals with hemophilia can be treated by intravenous infusion of the factor that they miss, over time, some individuals develop antibodies that prevent the infused factor from ...

New Data Show Revlimid(R) (lenalidomide) Offers Significant Survival Gainsfor People With Life-limiting Blood Cancer

Thursday, April 10th, 2008

According to data presented today at the 48th Annual Scientific Meeting of the British Society for Haematology (BSH), patients taking Revlimid® (lenalidomide) plus high dose dexamethasone for treatment of multiple myeloma experience a significant survival gain. On average, patients experienced nearly three extra years of life when treated with lenalidomide ...

Gore Revise Study Receives Approval From FDA

Wednesday, April 9th, 2008

FDA approval to proceed with the Gore REVISE (VasculaR AccEss ReVision with Viabahn® EndoproSthesis vs PercutanEous Transluminal Angioplasty) Study was announced today by W. L. Gore & Associates (Gore). The Gore REVISE Study is a randomized, multi-center clinical trial intended to establish efficacy and safety of the GORE VIABAHN® Endoprosthesis ...

FDA Reports More Deaths Linked To Contaminated Heparin

Wednesday, April 9th, 2008

The US Food and Drug Administration released an update yesterday, 8th April, showing a dramatic rise in the number of deaths that may be due to patients having allergic reactions to contaminated heparin. The agency puts the new figure at 62 deaths in the last 15 months, which is ...

Early Diagnosis Of Neurodegenerative Disease On The Horizon

Tuesday, April 8th, 2008

A new blood test that can give an early diagnosis of neurodegenerative disease and distinguish between Parkinson's and Alzheimer's disease could be launched this summer, reports Marina Murphy in SCI's Chemistry & Industry magazine.Manufacturer, Oklahoma-based proteomics company, Power3 Medical Products, said it plans to sell the test, NuroPro, which would ...

Neutropenia: Biosimilar Product From India Moves One Step Closer To European Market

Monday, April 7th, 2008

A biosimilar product for treating the negative effects that cancer chemotherapy can have on the white blood cells of patients is safe and exhibits an identical pharmacokinetic and pharmacodynamic profile compared to a reference product. This is the result of a clinical phase ...

Intracranial Hemorrhage Patients Better Off After Having Blood Pressure Lowered Even More

Monday, April 7th, 2008

Intracranial Hemorrhage Patients Better Off After Having Blood PressureLowered Even More An article in The Lancet Neurology suggests that inindividuals who have had intracranial hemorrhage, hematoma growth canbe reduced by lowering their blood pressure even further than whatexisting guidelines recommend.A patient's blood pressure can rapidly increase due to intracranialhemorrhage (bleeding ...

Breakthrough Research In Multiple Myeloma Treatment Flows From IMBCR, The Sole Independent Myelema Research Institute

Saturday, April 5th, 2008

The Institute for Myeloma and Bone Cancer Research (IMBCR), established in 2004 as a 501 c (3) non-profit organization, is headquartered in West Hollywood, California. IMBCR is the only independent non-profit cancer research institute working to find improved treatment, and ultimately a cure for multiple myeloma, a cancer of the ...